GlassScriptPhysician profile
Tabitha Martinez Randol
NPI 1073548913
$2,821.12
in general payments reported to CMS, 2019-2025
19 companies · $249 in 2025
The $249 reported for 2025 was more than what 80% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $197 · 2020: $351 · 2021: $385 · 2022: $468 · 2023: $448 · 2024: $723 · 2025: $249.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,420.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,420.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironshore Pharmaceuticals INC. | $1,217.03 | 2019-2024 | Jornay Pm |
| Supernus Pharmaceuticals, INC. | $468.50 | 2021-2025 | Qelbree, Qelbree |
| Corium, LLC | $253.74 | 2021-2025 | Azstarys |
| Cranial Technologies, INC | $161.68 | 2019-2025 | Doc Band |
| Tris Pharma INC | $150.28 | 2019-2023 | Dyanavel Xr |
| Neos Therapeutics, LP | $101.86 | 2020-2024 | Cotempla Xr-Odt |
| Pfizer INC. | $89.87 | 2019-2025 | |
| Collegium Pharmaceutical, INC. | $83.08 | 2025 | Jornay Pm |
| Adlon Therapeutics L.P. | $72.71 | 2019-2021 | |
| Genentech USA, INC. | $41.74 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $28.51 | 2020-2021 | |
| Merck Sharp & Dohme LLC | $27.25 | 2022-2025 | Vaxneuvance, Gardasil 9, Rotateq |
| Sanofi Pasteur INC. | $25.98 | 2021 | |
| Mission Pharmacal Company | $25.89 | 2019 | |
| Sanofi-Aventis U.S. LLC | $18.98 | 2024 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Seqirus USA INC | $15.73 | 2024 | Flucelvax |
| Vertical Pharmaceuticals, LLC | $14.18 | 2025 | Relexxii |
| Shire North American Group INC | $13.27 | 2019 | |
| Novartis Pharmaceuticals Corporation | $10.84 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tabitha Randol listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.